This session will feature PRO/CON debates on 4 topics in ILD that are relevant to cutting edge clinical practice and research. These will include the utility of bronchoalveolar lavage in fibrotic lung disease, change in FVC over 3 months as a clinical trial endpoint in IPF, formal testing for acid reflux in progressive pulmonary fibrosis, and whether IPF is an entity of the past.
• Analyze and understand IPF clinical trial results and endpoints and how these affect clinical practice and future research efforts
• Integrate available data on formal testing and treatment of gastroesophageal reflux in progressive fibrotic lung disease in to clinical practice
• Gauge the risks and potential benefits of bronchoalveolar lavage for patients with fibrotic lung disease
Mary Beth Scholand, MD
Andrew Wilson, MD, FRCP
Tamera Corte, MBBS, BSc(Med) , FRACP, PhD
Richard Jenkins, BM, MD, MRCP(UK), PhD
Tejaswini Kulkarni, MD, MPH
Nazia Chaudhuri, MB BCh, PhD, BSc
Ganesh Raghu, MD
PRO: Formal Testing for Abnormal Acid Reflux Should Be Performed in All Patients with IPF to Determine the Need for Anti-Reflux Therapy\
CON: Formal Testing for Abnormal Acid Reflux Should Be Performed in All Patients with IPF to Determine the Need for Anti-Reflux Therapy
PRO: Change in FVC at 3 Months is an Acceptable Primary Endpoint for IPF Clinical Trials
CON: 2. Change in FVC at 3 Months is an Acceptable Primary Endpoint for IPF Clinical Trials
PRO: BAL for Lymphocytosis Should be Performed in Patients with New Onset Fibrotic ILD
CON: 3. BAL for Lymphocytosis Should Be Performed in Patients with New Onset Fibrotic ILD
PRO: IPF is a Disease of the Recent Past